Skip to main content

Table 3 Factors associated with APRI score >1.5

From: HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study

  Proportion with APRI >1.5 (significant fibrosis) Odds ratio
(n = 726)
p value Adjusted odds ratio (n = 726) p value
Hepatitis C antibody status
 Negative 2.1% (11/531) 1.00   1.00  
 Positive 10.0% (23/231) 5.16 (2.50-10.65) <0.001 2.53 (1.03-6.23) 0.044
Hepatitis B surface antigen
 Positive 1.4% (2/146) 1.00   1.00  
 Negative 5.2% (32/616) 3.28 (0.89-12.02) 0.074 3.28 (0.85-12.71) 0.085
History of injecting drug use
 No 1.8% (11/603) 1.00   1.00  
 Yes 15.3% (23/150) 9.15 (4.40-19.01) <0.001 3.51 (1.39-8.89) 0.008
WHO stagea
 1–2 2.6% (16/605) 1.00   1.00  
 3–4 12.4% (18/145) 5.02 (2.52-10.02) <0.001 3.47 (1.51-7.99) 0.003
CD4 counta
  > 350 cells/mm3 3.9% (22/563) 1.00    
 201-350 cells/mm3 5.3% (7/132) 1.46 (0.62-3.42) 0.381   
  ≤ 200 cells/mm3 8.2% (4/49) 2.32 (0.80-6.67) 0.119   
Smoker at postnatal cohort enrolment
 No 2.7% (11/409) 1.00   1.00  
 Yes, current smoker 6.8% (23/340) 2.59 (1.26-5.33) 0.010 1.06 (0.46-2.42) 0.896
Age
 Per increasing year   1.10 (1.03-1.18) 0.007 1.08 (0.99-1.18) 0.070
Postnatal ARTb
 Yes 4.0% (10/253) 1.00   1.00  
 No 4.8% (24/500) 1.15 (0.55-2.41) 0.715 3.08 (1.23-7.74) 0.017
  1. aClosest to timing of liver function test measures bAt postnatal cohort enrolment